Shield Therapeutics plc (STX.L) LSE
Currency In GBp
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In GBp
Address
Northern Design Centre
Gateshead, NE8 3DF
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1915 118 500
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
63
First IPO Date
February 26, 2016
| Name | Title | Pay | Year Born |
| Anders Lundstrom | CEO, Interim CFO & Director | 445,855 | 1962 |
| Christian Schweiger | Co-Founder & Non Executive Director | 97,484 | 1966 |
| Lucy Kate Huntington-Bailey | General Counsel, Chief Compliance Officer & Company Secretary | 0 | N/A |
| Suzanne Wood | Group HR Director | 0 | N/A |
| Kate Armanetti | Senior Director of People & Culture | 0 | N/A |
| Carol Akinola | Head of Pharmacovigilance & Medical Information | 0 | N/A |
| Andrew Hurley | Chief Commercial Officer | 0 | 1969 |
| Santosh Shanbhag | Chief Financial Officer | 0 | 1978 |
Shield Therapeutics plc is a specialized pharmaceutical firm dedicated to developing and commercializing innovative drugs at various clinical stages to address significant unmet medical requirements. Their flagship product, Accrufer/Feraccru, is an oral, non-salt-based treatment specifically designed for adult patients experiencing iron deficiency, with or without associated anemia. The company is also advancing PT20, a novel iron-based phosphate binder that has successfully concluded its pivotal Phase II study for the management of hyperphosphatemia in individuals afflicted with chronic kidney disease. Established in 2008, Shield Therapeutics plc maintains its headquarters in Gateshead, United Kingdom.